Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RAPP-ID

Financiado

Development of RApid Point-of-Care test Platforms for Infectious Diseases

RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as vir... ver más

30/09/2016

JANSSEN PHARMACEUT...

16M€

Presupuesto del proyecto: 16M€

Líder del proyecto

JANSSEN PHARMACEUTICA NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 14 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2016-09-30

0% 100%

14 Participantes

JANSSEN PHARMACEUTICA NV

Lider

UANTWERPEN

N.D. | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

KTH

N.D. | Participante

Proyectos interesantes

PID2020-118904RB-C22 DESARROLLO DE TESTS RAPIDOS Y ULTRASENSIBLES PARA INFECCIONE... 74K€ Cerrado

PLEC2021-007739 Biosensores nanofotónicos para el diagnóstico y gestión clín... 370K€ Cerrado

Molecular Culture World’s first diagnostic test that can detect all bacterial... 5M€ Cerrado

PTQ-15-07422 Nuevos ensayos de PCR para la detección rápida y eficaz de g... 84K€ Cerrado

PTQ-17-09111 Desarrollo de un inmunoensayo ultrasensible y multiplexado p... 57K€ Cerrado

PRONTO self-PoweRed cONductimeter for digiTalization of rapid mOlec... 150K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 65 meses Fecha Inicio: 2011-04-01
Fecha Fin: 2016-09-30

Líder del proyecto

JANSSEN PHARMACEUTICA NV

TRL 4-5

Presupuesto del proyecto 16M€

Descripción del proyecto RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods. The platforms will also determine resistance to antimicrobial drugs. The research will focus on the biomarkers and pathogens involved in 1) Sepsis, 2) Lower Respiratory Tract Infections (LRTI), including Community-Acquired Pneumonia (CAP) and Ventilator-Associated Pneumonia (VAP), and 3) Tuberculosis (TB). Detection of bacteria, fungi and antibiotic resistance will mainly involve Nucleic Acid (NA) tests, whereas viral and host biomarker detection will mainly involve selective immunobinding with a probe or with a sensor surface. The diagnostic tests consist of in four functional modules: 1) sample collection and interfacing, 2) upconcentration and extraction, 3) signal and/or sample amplification, and 4) detection. RAPP-ID will integrate the minimum number of modules required for each disease/syndrome in a microfluidic cartridge, for which a breadboard reader with Graphical User Interface (GUI) provides the necessary optical/fluidic/electric/thermal interfaces. The integrated POCT will be validated on (spiked) reference samples and well characterised clinical samples and compared with the best reference standards and other standard available diagnostic tests.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores